SunTrust Initiates Coverage on Several Drug Manufacturers & Suppliers
More News related to ACL
- Novartis for Alcon (ACL)? Novartis Says "No" But Market Says "Yes"
- Despite Novartis Denial, UBS Makes A Strong Case That They Should Buy Alcon (ACL)
- Alcon (ACL) options active on 41K contacts as shares rally 5%
- Novartis (NVS) has no plans to buy out Alcon (ACL) minority shares - Bloomberg
- Alcon (ACL) Jumps On Takeover Chatter
More News related to AGN
- Spectrum Pharma (SPPI) and Handok Pharma Announce Plans for Apaziquone Development in South Korea
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Spectrum Pharma (SPPI) To Collaborate with Nippon Kayaku to Develop and Commercialize Apaziquone in Asia
- The Lowe Law Firm Files Suit over Alleged Botox Overdose
- Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution
More News related to CEPH
- Cephalon (CEPH) Files Patent Infringement Lawsuit Against Teva (TEVA)
- Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
- Jefferies & Co Upgrades Cephalon (CEPH) to Buy
- Cephalon (CEPH) options active on flat volatility; shares sell off 7% on clinical trial
- Unusual 11 Mid-Day Movers 11/23: ABIO, SEED, FNET, CDTI Higher; NYNY, GGR, TTIL, PEET Lower
More News related to New Coverage
- JANCO Partners Downgrades Energy Conversion Devices (ENER) to Sell
- Feltl & Co. Downgrades ArcSight (ARST) to Sell
- Credit Suisse Downgrades Comcast (CMCSA) to Neutral
- Citi Downgrades AK Steel (AKS) to Hold
- Citi Downgrades Netflix (NFLX) to Hold
SunTrust initiates coverage on Alcon (NYSE: ACL), Allergan (NYSE: AGN), Ista Pharmaceuticals (Nasdaq: ISTA), Sepracor (Nasdaq: SEPR), & Shire (Nasdaq: SHPGY) with a Buy.\
SunTrust's price target on ACL is $155, AGN $58, ISTA $5, SEPR $24 & SHPGY is $53.
SunTrust initiates coverage on Cephalon (Nasdaq: CEPH) & Forest Labs (NYSE: FRX) with a Neutral rating.
Related Categories
New CoverageStocks Mentioned
+2.92
-0.07Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
